ライフサイエンスコーパス: beta-lactam

1 n the native S. aureus PBPs are inhibited by beta-lactams.

2 one of the highly effective antibacterials, beta-lactams.

3 istance to the carbapenem imipenem and other beta-lactams.

4 anhydride to transform aliphatic amines into beta-lactams.

5 inhibitor could restore the effectiveness of beta-lactams.

6 abolite levels that occur during exposure to beta-lactams.

7 these pathogens test as susceptible to some beta-lactams.

8 L) producing bacteria has limited the use of beta-lactams.

9 allergic reactions to penicillins and other beta-lactams.

10 rturbed evolved prior to the clinical use of beta-lactams.

11 t strains with their inhibition by different beta-lactams.

12 ast bactericidal effect, are not inferior to beta-lactams.

13 olecules that restore sensitivity of MRSA to beta-lactams.

14 he detection ranges were 0.26-3.56 ng/mL for beta-lactams, 0.04-0.98 ng/mL for tetracyclines, 0.08-2.

15 of beta-lactamases, enzymes that inactivate beta-lactams, a class of antibiotics that has been a the

16 nhibit the full range of MBLs and potentiate beta-lactam activity against producer pathogens.

17 gainst Enterobacteriaceae and restoration of beta-lactam activity in a broad range of MDR Gram-negati

18 ying beta-lactam allergies to safely promote beta-lactam administration among these patients is warra

19 Continuous beta-lactam administration was not independently associa

20 In a multivariable model, intermittent beta-lactam administration, higher Acute Physiology and

21 adjust both the dose and dosing interval of beta-lactam agents allows the treatment of strains with

22 Beta-lactam agents have the highest rates of resistance

23 nam and the tolerability of such alternative beta-lactams, all subjects underwent skin tests with cep

24 ent programs aimed at accurately identifying beta-lactam allergies to safely promote beta-lactam admi

25 Predictors of interest were history of beta-lactam allergy and receipt of preferred beta-lactam

26 Guidance for beta-lactam allergy in children is given in a separate s

27 e the burden and clinical impact of reported beta-lactam allergy on patients seen by infectious disea

28 Of 827 patients with reported beta-lactam allergy over 15 months, beta-lactam therapy

29 beta-lactam allergy skin testing (BLAST) is recommended

30 sociation study of the genetic predictors of beta-lactam allergy to better understand the underlying

31 Among 507 patients, 95 (19%) reported beta-lactam allergy; preferred therapy was a beta-lactam

32 us 146/10,215 (1.4%) patients who received a beta-lactam alone (crude RR 0.61, 95% CI 0.45, 0.83).

33 alone versus 7,314/52,504 [13.9%] receiving beta-lactam alone).

34 resistant to multiple antibiotics, including beta-lactams, aminoglycosides, fluoroquinolones, and pol

35 s study chooses four classes of antibiotics, beta-lactam (ampicillin and penicillin), quinolone (enox

36 Because combination therapy using both a beta-lactam and a second antibiotic suppressing the smal

37 aceae (3GC-R EB), Dutch guidelines recommend beta-lactam and aminoglycoside combination therapy or ca

38 amide-streptogramin, bacitracin, vancomycin, beta-lactam and aminoglycoside resistance genes were the

39 lin resistance in Staphylococcus aureus, and beta-lactam and co-trimoxazole resistance in Streptococc

40 deficiency potentiates antibiotics from the beta-lactam and quinolone classes.

41 cation of the two side chains carried by the beta-lactam and the five-membered rings of the carbapene

42 isopenicillin N synthase (IPNS) installs the beta-lactam and thiazolidine rings of the penicillin cor

43 atients with immediate allergic reactions to beta-lactams and 1124 paired control subjects from Spain

44 nditions were lower than those observed with beta-lactams and close to those observed with amikacin.

45 d inhibition of MBLs by beta-lactams and non-beta-lactams and illustrate the utility of PrOF NMR for

46 for the mechanisms and inhibition of MBLs by beta-lactams and non-beta-lactams and illustrate the uti

47 tion between beta-arylated alpha-methylidene-beta-lactams and terminal olefins was developed.

48 ined and empiric therapy with broad-spectrum beta-lactams and/or aminoglycosides and/or fluoroquinolo

49 s either single agent alone (vancomycin or a beta-lactam) and SSI was evaluated.

50 Antibiotic treatment was primarily using beta-lactams, and 37% of patients received rifampin.

51 b transpeptidase domain is a major target of beta-lactams, and therefore it is important to attain a

52 The mechanism of the beta-lactam antibacterials is the functionally irreversi

53 ould effectively inhibit PrkA and potentiate beta-lactam antibiotic activity to varying degrees.

54 ons in synaptic contact were reversed by the beta-lactam antibiotic ceftriaxone.

55 eltadacA mutants are highly sensitive to the beta-lactam antibiotic cefuroxime.

56 with vancomycin plus 1 other antipseudomonal beta-lactam antibiotic combination (adjusted odds ratio,

57 Optimization of beta-lactam antibiotic dosing for critically ill patient

58 athways that have evolved to the three other beta-lactam antibiotic families: penicillin/cephalospori

59 r conditions of induction of resistance to a beta-lactam antibiotic identified two signaling muropept

60 r the introduction of this second generation beta-lactam antibiotic into clinical practice.

61 a an active process and was inhibited by the beta-lactam antibiotic oxacillin, which slowed inactivat

62 genum is the main industrial producer of the beta-lactam antibiotic penicillin, the most commonly use

63 erant and hypersensitive patients taking the beta-lactam antibiotic piperacillin and the threshold re

64 every new user of an oral fluoroquinolone or beta-lactam antibiotic prescription with at least 24 mon

65 omal AmpC beta-lactamase is a major cause of beta-lactam antibiotic resistance in the Gram-negative b

66 Here we show that the protein conferring beta-lactam antibiotic resistance, penicillin-binding pr

67 The beta-lactam antibiotic temocillin (6-alpha-methoxy-ticar

68 herapy with vancomycin and 1 antipseudomonal beta-lactam antibiotic throughout the first week of hosp

69 demonstrate that bacterial persisters, under beta-lactam antibiotic treatment, show less cytoplasmic

70 l disturbance, severe neutropenia, and prior beta-lactam antibiotic use.

71 d IV vancomycin plus 1 other antipseudomonal beta-lactam antibiotic, 157 patients (8.2%) had antibiot

72 sion of beta-lactamase in the absence of any beta-lactam antibiotic, thus indicating that they serve

73 (AKI) compared with vancomycin plus 1 other beta-lactam antibiotic.

74 m or vancomycin plus 1 other antipseudomonal beta-lactam antibiotic.

75 The paper card can also detect substandard beta lactam antibiotics using an iodometric back-titrati

76 ed in presence of other structurally related beta-lactam antibiotics (amoxicillin, oxacillin, penicil

77 Resistance of S. aureus strains to beta-lactam antibiotics (eg, oxacillin) depends on the p

78 he main bacterial mechanism of resistance to beta-lactam antibiotics and are a significant challenge

79 -beta-lactamases (MBLs) hydrolyze almost all beta-lactam antibiotics and are unaffected by clinically

80 a-lactamases catalyze the hydrolysis of most beta-lactam antibiotics and hence represent a major clin

81 beta-Lactamases (BLs) able to hydrolyze beta-lactam antibiotics and more importantly the last re

82 The targets of beta-lactam antibiotics are bacterial DD-peptidases that

83 beta-Lactam antibiotics are often coadministered with in

84 PBP2a effectively discriminates against the beta-lactam antibiotics as potential inhibitors, and in

85 with intermittent dosing, administration of beta-lactam antibiotics by continuous infusion in critic

86 uct complex crystal structures of KPC-2 with beta-lactam antibiotics containing hydrolyzed cefotaxime

87 ant Enterobacteriaceae are resistant to most beta-lactam antibiotics due to the production of the Kle

88 tified that reversed intrinsic resistance to beta-lactam antibiotics in a manner distinct from beta-l

89 amases are enzymes that confer resistance to beta-lactam antibiotics in bacteria, and there is a crit

90 g continuous versus intermittent infusion of beta-lactam antibiotics in critically ill patients with

91 e, the pauA2 mutant became more sensitive to beta-lactam antibiotics in human serum.

92 epair and the manifestation of resistance to beta-lactam antibiotics in many Enterobacteriaceae and P

93 Reported allergy to beta-lactam antibiotics is common and often leads to unn

94 The target of beta-lactam antibiotics is the D,D-transpeptidase activi

95 The efficacy of beta-lactam antibiotics is threatened by the emergence a

96 Resistance to beta-lactam antibiotics mediated by metallo-beta-lactama

97 Tipper-Strominger hypothesis stipulates that beta-lactam antibiotics mimic the acyl-D-Ala-D-Ala moiet

98 Our data indicate that beta-lactam antibiotics should be included in the treatm

99 ant was also significantly more sensitive to beta-lactam antibiotics than Schu S4.

100 In the presence of beta-lactam antibiotics these altered cell-wall segments

101 (CLSI) lowered the MIC breakpoints for many beta-lactam antibiotics to enhance detection of known re

102 taphylococcus aureus (MRSA) are resistant to beta-lactam antibiotics, which inhibit bacterial cell wa

103 h continuous versus intermittent infusion of beta-lactam antibiotics.

104 a-Lactamases enable resistance to almost all beta-lactam antibiotics.

105 of these kinases in regulating resistance to beta-lactam antibiotics.

106 tors of resistance or susceptibility against beta-lactam antibiotics.

107 splays a high susceptibility to lysozyme and beta-lactam antibiotics.

108 s organism extremely difficult to treat with beta-lactam antibiotics.

109 e bulges and lyse, resembling treatment with beta-lactam antibiotics.

110 singly widespread resistance of pathogens to beta-lactam antibiotics.

111 ailable in the UK and a description of known beta-lactam antigenic determinants.

112 and 23S rRNA) associated with resistance to beta-lactam antimicrobials, macrolides, or fluoroquinolo

113 val [CI], 1.45-5.42), as was narrow-spectrum beta-lactams (aOR, 3.54; 95% CI, 1.98-6.33), and appropr

114 n Denmark, we quantified four broad-spectrum beta-lactam AR genes (ARG; bla(TEM), bla(SHV), bla(OXA)

115 Allergic reactions to beta-lactams are among the most frequent causes of drug

116 However, because beta-lactams are chemical and structural mimics of the n

117 f exchanging the removable components and of beta-lactams are confirmed and maybe also a potential be

118 beta-Lactams are generally recommended in clean surgical

119 ble Staphylococcus aureus (MSSA) infections, beta-lactams are recommended for definitive therapy; how

120 This class of monocyclic beta-lactams are stable to metallo-beta-lactamases and h

121 the concern of complex drug responses, many beta-lactams are typically ruled out if ESBL-producing p

122 h as alpha-quaternary beta-homo prolines and beta-lactams, are also prepared in two- to three-steps f

123 ly reduced aminoglycoside, tetracycline, and beta-lactam ARG levels relative to anaerobic units, alth

124 "Total" beta-lactam ARG levels were significantly higher in M ve

125 for immediate hypersensitivity reactions to beta-lactams, aspirin, and nonsteroidal anti-inflammator

126 to delineate an advantageous approach toward beta-lactams based on a two-step, one-pot protocol: an i

127 eport the discovery of compound 4a, a potent beta-lactam-based monoacylglycerol lipase (MGL) inhibito

128 Genes involved in IR to beta-lactams belonged to HLA type 2 antigen processing,

129 hen combined with ceftazidime, the novel non-beta-lactam beta-lactamase inhibitor avibactam provides

130 implications for the use of next-generation beta-lactam-beta-lactamase inhibitor combinations.

131 bactam and ceftazidime/avibactam are 2 novel beta-lactam/beta-lactamase combination antibiotics.

132 Resistance to the novel beta-lactam/beta-lactamase inhibitor combination ceftazi

133 Our findings should not be extended to beta-lactam/beta-lactamase inhibitor combinations in dev

134 tive alternative drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment

135 sistant to cephalosporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors, multidrug resista

136 Previous use of beta-lactam/beta-lactamase or carbapenems and recent hos

137 o, 1.65 [95% CI, 1.15-2.37]) and exposure to beta-lactams/beta-lactamase inhibitors (risk ratio, 1.78

138 d-BTZ complexes most closely resemble beta-lactam binding to B1 MBLs, but feature an unprecede

139 ections (BSIs) in patients presenting with a beta-lactam (BL) allergy is often a difficult decision g

140 ests (DPT) are commonly performed as part of beta-lactam (BL) allergy workup, in case of negative ski

141 oposed an algorithm for diagnosing immediate beta-lactam (BL) allergy.

142 Pneumococcus resists beta-lactams by expressing variants of its target enzyme

143 r pathogen Listeria monocytogenes to various beta-lactams by inhibiting the PASTA kinase PrkA.

144 y trapping experiments, thus confirming that beta-lactams can be designed that are capable of releasi

145 A diverse range of polysubstituted beta-lactams can be generated by systematic variation of

146 ication followed by reductive removal of the beta-lactam carbonyl moiety.

147 serovar Typhi strain with resistance against beta-lactams, cephalosporins (extended-spectrum beta-lac

148 robial resistance determinants for different beta-lactams, ciprofloxacin, and tetracyclines on multip

149 as threatened the clinical usefulness of the beta-lactam class of antimicrobials.

150 d IV vancomycin plus 1 other antipseudomonal beta-lactam combination therapy at 1 of 6 large children

151 genes, were used to predict resistance to 4 beta-lactams commonly used in the empiric treatment of n

152 sponses were challenged with the alternative beta-lactams concerned.

153 The synthesis of a small set of beta-lactams containing isocyanate precursors is describ

154 s vancomycin, bacitracin, daptomycin and the beta-lactam-containing penicillins, cephalosporins and n

155 ours; P = .01) and increased narrow-spectrum beta-lactam (control 42 hours, rmPCR 71 hours, rmPCR/AS

156 Using quantitative modeling, we show that beta-lactams could still effectively treat pathogens pro

157 A novel series of beta-lactam derivatives that was designed and synthesize

158 , particularly plasmid-encoded resistance to beta lactam drugs, poses an increasing threat to human h

159 ubgraphs were noted, one containing the five beta-lactam drugs and the other containing both sulfonam

160 he type of travel, diarrhea, and exposure to beta-lactams during the travel.

161 days), and long treatments (>/=21 days) with beta-lactams, either as monotherapy (0.48) or in combina

162 E), blaNDM-1, and selected extended-spectrum beta-lactam (ESBL) resistant bacteria and genes in 12 ho

163 cephalosporins, which are antibiotics in the beta-lactam family that target cell-wall biosynthesis.

164 ination of vancomycin and antistaphylococcal beta-lactams for methicillin-resistant Staphylococcus au

165 The use of non-carbapenem beta-lactams for the treatment of ESBL infections has yi

166 term (</=60 min) infusion of antipseudomonal beta-lactams for the treatment of patients with sepsis w

167 ATION: Prolonged infusion of antipseudomonal beta-lactams for the treatment of patients with sepsis w

168 d multicomponent method for the synthesis of beta-lactams from imines, aryl halides, and CO has been

169 ients who received definitive therapy with a beta-lactam had 35% lower mortality compared with patien

170 Patients who received empiric therapy with a beta-lactam had similar mortality compared with those wh

171 's repertoire that can be activated with the beta-lactam hapten and/or an imbalance in immune regulat

172 ctions, even when in vitro activity to other beta-lactams has been demonstrated.

173 While beta-lactams have a relatively slow effect, both tested

174 e groups of enzymes, their substrates and of beta-lactams have led to the conclusion that beta-lactam

175 ose who especially require these alternative beta-lactams, however, we recommend pretreatment skin te

176 on of beta-lactamases, enzymes that catalyze beta-lactam hydrolysis.

177 Delayed-type beta-lactam hypersensitivity develops in subset of patie

178 beta-Lactam hypersensitivity has been classified accordi

179 study was to use piperacillin as a model of beta-lactam hypersensitivity to study the nature of the

180 ting T cells are detectable in patients with beta-lactam hypersensitivity.

181 beta-lactam allergy; preferred therapy was a beta-lactam in 72 (76%).

182 tazidime) complexes with PBP2a-each with the beta-lactam in the allosteric site-defined (with precedi

183 D platforms for detecting resistance against beta-lactams in 72 highly resistant isolates of Escheric

184 lead to the formation of trans-disubstituted beta-lactams in excellent yields and selectivities.

185 ing corresponding alpha-alkylidene-beta-aryl-beta-lactams in good isolated yields (41-83%) with exclu

186 stituted imines to produce novel spirocyclic beta-lactams in good yields and selectivity.

187 ersus short-term infusion of antipseudomonal beta-lactams in patients with sepsis.

188 term intravenous infusion of antipseudomonal beta-lactams in patients with sepsis.

189 of cardiac procedures showed superiority of beta-lactams in preventing superficial and deep chest SS

190 of E. coli PBP1b bound to multiple different beta-lactams in the transpeptidase active site and compl

191 ary regarding the effectiveness of prolonged beta-lactam infusion.

192 trate the direct incorporation of monocyclic beta-lactams into a variety of molecular architectures.

193 Bacterial resistance to beta-lactams is achieved by the production of beta-lacta

194 the comparative effectiveness of individual beta-lactams is unknown.

195 lar to mecA, mecC confers resistance against beta-lactams, leading to the phenotype of methicillin-re

196 dical reasons) with beta-lactam monotherapy, beta-lactam-macrolide combination therapy, or fluoroquin

197 ose deoxysugar, and antibiotics derived from beta-lactams, macrolides, and aminocoumarins.

198 Mechanical activation of a beta-lactam mechanophore using ultrasound induces a form

199 ic site-to-active site communication and for beta-lactam mimicry of the peptidoglycan substrates, as

200 ne are epidemiology of allergic reactions to beta-lactams, molecular structure, formulations availabl

201 ic ring-opening polymerization of an altrose beta-lactam monomer (alt-lactam).

202 inoglycoside combination therapy compared to beta lactam monotherapy in patients with sepsis.

203 al (n = 1737) demonstrated noninferiority of beta-lactam monotherapy (n = 506) vs beta-lactam plus ma

204 a in the study period; 1019 (71.9%) received beta-lactam monotherapy and 399 (28.1%) received beta-la

205 beta-Lactam monotherapy and beta-lactam plus macrolide c

206 of hospital stay between children receiving beta-lactam monotherapy and combination therapy (median,

207 ombination therapy conferred no benefit over beta-lactam monotherapy for children hospitalized with c

208 hically confirmed pneumonia and who received beta-lactam monotherapy or beta-lactam plus macrolide co

209 580) failed to demonstrate noninferiority of beta-lactam monotherapy vs beta-lactam plus macrolide co

210 To compare the effectiveness of beta-lactam monotherapy vs beta-lactam plus macrolide co

211 llowing deviations for medical reasons) with beta-lactam monotherapy, beta-lactam-macrolide combinati

212 We defined the referent as beta-lactam monotherapy, including exclusive use of an o

213 -0.6% to 5.2%) in 90-day mortality favoring beta-lactam monotherapy.

214 ons of 30% to 43% in mortality compared with beta-lactam monotherapy.

215 Addition of the beta-lactam motif to the current repertoire of covalent

216 Beta-lactam, multidrug efflux pumps, fluoroquinolone, an

217 determinants of immediate reactions (IR) to beta-lactams (n = 19), NAR against aspirin (n = 12) and

218 BL allergy who received either a BL or a non-beta-lactam (NBL).

219 troduction of the compactin pathway into the beta-lactam-negative P. chrysogenum DS50662, a new cytoc

220 Deprotection of the beta-lactam nitrogen atom can be achieved by lithium in

221 uce and secrete the antibiotic penicillin, a beta-lactam nonribosomal peptide, by taking genes from a

222 133 putative instances of resistance to the beta-lactams of interest identified by WGS, only 87 (65%

223 Combinations of beta-lactams of the carbapenem class, such as meropenem,

224 In all, 70,101 procedures (52,504 beta-lactam only, 5,089 vancomycin only, and 12,508 comb

225 ose pulsed antibiotic treatment (PAT) with a beta-lactam or macrolide alters both host and microbiota

226 The crystal structures of three beta-lactams (oxacillin, cefepime, ceftazidime) complexe

227 s failed to demonstrate clinical benefits of beta lactam plus aminoglycoside combination therapy comp

228 Use of a beta-lactam plus an oral or parenteral macrolide (azithr

229 rity of beta-lactam monotherapy (n = 506) vs beta-lactam plus macrolide combination therapy (n = 566)

230 effectiveness of beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy among a c

231 beta-Lactam monotherapy and beta-lactam plus macrolide combination therapy are both

232 pneumonia, antibiotic therapy consisting of beta-lactam plus macrolide combination therapy or fluoro

233 dy populations of 1188 to 24,780) found that beta-lactam plus macrolide combination therapy was assoc

234 noninferiority of beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy, with an

235 linical stability on hospital day 7 favoring beta-lactam plus macrolide combination therapy.

236 and who received beta-lactam monotherapy or beta-lactam plus macrolide combination therapy.

237 -lactam monotherapy and 399 (28.1%) received beta-lactam plus macrolide combination therapy.

238 Use of combination prophylaxis with a beta-lactam plus vancomycin is increasing; however, the

239 a infections and confirm that aztreonam-like beta-lactams plus nonclassical beta-lactamase inhibitors

240 fluoroquinolone prescription compared with a beta-lactam prescription using multivariate regression w

241 he binding of both inhibitors and hydrolyzed beta-lactam products to SPM-1.

242 is important in securing good yields for the beta-lactam products.

243 beta-Lactams represent one of the most important classes

244 nal linkage between specific determinants of beta-lactam resistance (e.g. beta-lactamase) and redox p

245 lead to antibiotic resistance; for example, beta-lactam resistance by L,D-transpeptidase activities.

246 s reaction regulates gene expression for the beta-lactam resistance enzyme, beta-lactamase.

247 aluated for identification of PBP2a-mediated beta-lactam resistance in human and animal clinical isol

248 ves was screened for the ability to suppress beta-lactam resistance in Mycobacterium smegmatis.

249 f laboratory testing to detect mecC-mediated beta-lactam resistance in Staphylococcus aureus Kriegesk

250 strate viability, the PAD was used to detect beta-lactam resistance in wastewater and sewage and iden

251 ction, detoxification and aminoglycoside and beta-lactam resistance.

252 pGpp from antibiotic tolerance to high-level beta-lactam resistance.

253 idase activity of PBPs and to broad-spectrum beta-lactam resistance.

254 Beta-lactam resistant clinical isolates of Streptococcus

255 Here we used the high-level beta-lactam resistant S. oralis Uo5 as donor in transfor

256 e dynamics of the Sao Paulo MBL (SPM-1) from beta-lactam-resistant Pseudomonas aeruginosa.

257 ence of two oxidative cyclizations, with the beta-lactam ring being installed first and the thiazolid

258 is fully compatible with the highly unstable beta-lactam ring of carbapenems and that the triazole ri

259 nitrogen atom to provide the cis-substituted beta-lactam ring preferentially.

260 he pro-S-CCys,beta-H bond for closure of the beta-lactam ring, and the CVal,beta-H bond for installat

261 Nonetheless, beta-lactams showed mycobactericidal activity in combina

262 etween these enzymes' active site structure, beta-lactam specificity and metal content.Carbapenem-res

263 ted under the reaction conditions, including beta-lactam-, steroid-, and sugar-derived ones, leading

264 hese results indicated noninferiority of the beta-lactam strategy.

265 attractive entry to a variety of monocyclic beta-lactam structures related to monobactams and nocard

266 mber of amino acids that interact with bound beta-lactam substrates.

267 e mechanistic aspects of how Mtb responds to beta-lactams such as Amoxicillin in combination with Cla

268 t was the widespread use of first generation beta-lactams such as penicillin in the years prior to th

269 mation and increases antibiotic tolerance to beta-lactams, suggesting that HQNO-dependent cell autoly

270 oxamates facilitated syntheses of monocyclic beta-lactams suitable for incorporation of a thiomethyl

271 ell-based time-kill assays show BTZs restore beta-lactam susceptibility of Escherichia coli-producing

272 en optimized for inactivation of the unusual beta-lactam targets of Mycobacterium tuberculosis or for

273 ime, and decreased activity toward all other beta-lactams tested.

274 Gold-catalyzed hydroarylation reaction of beta-lactam-tethered allenyl indoles gives azeto-oxepino

275 s detection of four families of antibiotics (beta-lactams, tetracyclines, quinolones and sulfonamides

276 qualitative analysis, the cut-off values of beta-lactams, tetracyclines, quinolones and sulfonamides

277 4.5-fold greater odds of receiving preferred beta-lactam therapy (95% confidence interval, 2.4-8.2; P

278 ne periods, 50% (124/246) received preferred beta-lactam therapy based on history, compared with 60%

279 In contrast, patients who received preferred beta-lactam therapy had a similar risk of adverse events

280 RMD platforms can help inform empiric beta-lactam therapy in cases where bla genes are not det

281 Avoidance of preferred beta-lactam therapy in patients who report allergy is as

282 reported beta-lactam allergy over 15 months, beta-lactam therapy was preferred among 632 (76%).

283 When beta-lactam therapy was preferred, 25 (35%) did not rece

284 ders, patients who did not receive preferred beta-lactam therapy were at greater risk of adverse even

285 al ASPs resulted in greater use of preferred beta-lactam therapy without increasing the risk of adver

286 beta-lactam allergy and receipt of preferred beta-lactam therapy.

287 bactam should be considered when determining beta-lactam therapy.

288 oportion of patients receiving the preferred beta-lactam therapy.

289 prove beneficial as treatments adjunctive to beta-lactam therapy.

290 allows cell-wall biosynthesis, the target of beta-lactams, to continue even in the presence of typica

291 beta-lactam treatment of MRSA skin infection exacerbates

292 he majority of cases were treated with other beta-lactams, trimethoprim-sulfamethoxazole, or vancomyc

293 ceipt of 2 antimicrobials (vancomycin plus a beta-lactam) versus either single agent alone (vancomyci

294 quinolone and 3,543,797 patients receiving a beta-lactam were included in the analysis.

295 Enantiopure 4-formyl-beta-lactams were deployed as synthons for the diastereo

296 Whereas beta-lactams were responsible for strong cell morphology

297 beta-lactamase can catalyze hydrolysis of a beta-lactam while that of a DD-peptidase cannot?

298 Combining an antistaphylococcal beta-lactam with vancomycin may shorten the duration of

299 Here, we compared beta-lactams with vancomycin for empiric and definitive

300 d annulations allowed the formation of fused beta-lactams without harming the sensitive four-membered